Stevanato Group S.p.A (STVN) Cash from Investing Activities (2020 - 2026)
Stevanato Group S.p.A (STVN) posted quarterly Cash from Investing Activities of -$82.4 million for Q1 2026, down 10.81% year-over-year from -$92.4 million in Q1 2025, and up 25.0% quarter-over-quarter from -$109.9 million in Q4 2025.
Stevanato Group S.p.A (STVN) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Stevanato Group S.p.A (STVN) has reported Cash from Investing Activities for 7 consecutive years, with -$82.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 10.81% year-over-year to -$82.4 million; the TTM figure through Mar 2026 stood at -$316.2 million (down 5.85% YoY), while the FY2025 annual figure was -$317.7 million, up 4.17% from the prior year.
- Cash from Investing Activities advanced to -$82.4 million in Q1 2026 per STVN's latest filing, from -$109.9 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$43.6 million in Q3 2022 and bottomed at -$143.9 million in Q3 2023.
- Historically, Cash from Investing Activities has averaged -$84.6 million across 5 years, with a median of -$81.3 million in 2022.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities sank 230.4% — and 2024, when it surged 63.68%.
- Stevanato Group S.p.A's Cash from Investing Activities stood at -$70.3 million in 2022, then slumped by 41.27% to -$99.3 million in 2023, then grew by 2.08% to -$97.2 million in 2024, then decreased by 13.0% to -$109.9 million in 2025, then gained by 25.0% to -$82.4 million in 2026.
- Business Quant data shows STVN's Cash from Investing Activities at -$82.4 million in Q1 2026, -$109.9 million in Q4 2025, and -$56.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | -26.60 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | -241.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | -222.00 Mn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | -383.65 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | -461.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | -43.20 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | -87.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | -90.00 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | -117.00 Mn |
| 10 | Stevanato Group S.p.A | 6.18 Bn | 6.07 Bn | 100.91 Mn | -74.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -74.26 Mn |
| Jun 30, 2026 | -74.26 Mn |
| Mar 31, 2026 | -82.42 Mn |
| Mar 31, 2026 | -82.42 Mn |
| Dec 31, 2025 | -109.89 Mn |
| Dec 31, 2025 | -109.89 Mn |
| Sep 30, 2025 | -56.35 Mn |
| Sep 30, 2025 | -56.35 Mn |
| Jun 30, 2025 | -67.58 Mn |
| Jun 30, 2025 | -67.58 Mn |
| Mar 31, 2025 | -74.38 Mn |
| Mar 31, 2025 | -74.38 Mn |
| Dec 31, 2024 | -97.24 Mn |
| Dec 31, 2024 | -97.24 Mn |
| Sep 30, 2024 | -52.28 Mn |
| Sep 30, 2024 | -52.28 Mn |
| Jun 30, 2024 | -74.84 Mn |
| Jun 30, 2024 | -74.84 Mn |
| Mar 31, 2024 | -110.93 Mn |
| Mar 31, 2024 | -110.93 Mn |